Sanochemia Pharmazeutika Aktiengesellschaft - Austria
| Държава: | Австрия |
| Кратка информация: | SANOCHEMIA has elected to focus on the development and manufacture of novel drugs and diagnostics in selected indication areas. These include indications such as neurodegeneration, pain and oncology, as well as diagnostics based on contrast media. Our products address previously unmet medical need and offer the potential of significant returns. The Specialty Pharma Company As an innovative and flexible pharmaceutical specialist, we are active in high-potential segments of the pharmaceutical market. This positioning allows us to maximise the potential in our core business areas of development and production. Our expertise lies in rapidly and efficiently tapping previously unexploited potential in known substances by means of new administration forms and application technologies. The in-house development of stereo-selective synthetic substances based on patented processes is key to our long-term growth. Our expertise in this and other areas allows us to offer a wide range of contract synthesis and manufacturing services. The SANOCHEMIA Group consists of three operational divisions: The PRODUCTION Division is engaged in the synthesis of active pharmaceutical substances (APIs), drug formulation and pharmaceutical production. These activities are performed either on behalf of the Human Pharmaceuticals Division or on a contract manufacturing basis and are, in part, based on patent-protected processes. The range of services provided by this division spans the chemical synthesis of innovative APIs to the manufacture of drugs and clinical diagnostics. The HUMAN PHARMACEUTICALS Division is primarily responsible for the Group's diagnostic activities. Our most important radiological products include a range of x-ray imaging agents and the MRT imaging agent launched in Germany in March 2008. The extension of SANOCHEMIA's product portfolio through the inclusion of a therapeutic, tolperisone, has added to this segment's revenue-generating potential. Our RESEARCH & DEVELOPMENT Division is responsible for the Group's development activities. Our competitive advantage lies in a combination of assessing the clinical potential of our drug candidates and in the speedy performance of pre-clinical and clinical trials. We prefer to target substances that, in addition to licensing revenues, also have the potential to generate additional added value through the use of our state-of-the-art synthesis plant and pharmaceutical production facilities. VETERINARY PHARMACEUTICALS: As a result of the acquisition of Alvetra & Werfft GmbH, Sanochemia now holds a veterinary medical product portfolio with established distribution channels - some of which in the form of subsidiaries - in CEE markets, the Middle East and South-East Asia. This latest acquisition underpins the international expansion of Sanochemia and also generates synergy effects in the areas of production, administration and drug development. Strategy "What we develop we can also produce" We concentrate on those segments of the value-added chain where our past success have enabled us to accumulate expertise and experience. These include the synthesis of active pharmaceutical ingredients (APIs), pre-clinical and clinical development and regulatory procedures. This strategy also encompasses being able to produce everything we develop - a key to retaining substance-specific knowledge in-house and achieving long-term competitive advantages. Short development times, rapid marketing authorisations and early product launches are other central aspects of our strategy. Our clearly-definded strategy as a Specialty Pharmaceuticals Company, the selection of high-potential therapeutic areas and the on-going internationalisation of our operations have placed us in a strong position from which to exploit the opportunities for growth generated by our operational divisions History The modern SANOCHEMIA Pharmazeutika AG was established by Dr. Werner Frantsits on 13. 11. 1990. Initial operations focussed on the manufacture and sale of human pharmaceuticals. True to its principle of retaining product-specific knowledge in-house, SANOCHEMIA has accumulated a comprehensive resource of pharmaceutical expertise over the years. This and the concentration on specific fields enables SANOCHEMIA to offer a unique and constantly expanding range of highly qualified standards and technologies for drugs, x-ray contrast media and imaging agents. Following its acquisition of a stake in Goldham Pharma GmbH, Germany, in 1999, SANOCHEMIA secured a foothold in a new business area – that of imaging agents. The purchase of the remaining shares in this company in 2002 allowed the company to form the core of today’s SANOCHEMIA Diagnostics operations. This and other subsequent acquisitions and projects were made possible by the company’s IPO on 12 May 1999, since which time SANOCHEMIA Pharmazeutika AG has been listed on the Frankfurt Stock Exchange. 1990 Founding of SANOCHEMIA Pharmazeutika AG on 13 November 1990 1995 Filing of patent applications covering synthetic manufacturing process for galantamine 1996 First patent awarded for galantamine synthesis and, with it, global patent protection 1998 Cooperation agreements signed with Janssen (Johnson & Johnson) and Shire Pharmaceuticals Merger with Waldheim Pharmazeutika 1999 Alzheimer’s Conference in Amsterdam reports on galantamine’s dual mechanism of action IPO 2000 Acquisition of 50% stake in Goldham Pharma First registration of Reminyl (Alzheimer’s drug based on galantamine) in Europe Award of the final synthesis patent for the industrial synthesis of galantamine Acquisition of a further 25% stake in Goldham Launch of Scanlux (first generic x-ray contrast medium) in Austria and Germany 2001 Regulatory approval granted for Reminyl (containing galantamine) in the USA Founding of SANOCHEMIA UK FDA approval of synthesis plant for galantamine (and approval for synthetically manufactured galantamine) 2002 EU marketing authorisation process for synthetic galantamine completed SANOCHEMIA Diagnostics established 2003 SANOCHEMIA Diagnostics International founded in Switzerland 2004 SANOCHEMIA Corporation established in US 2005 Opening of representation offices in China and India 2006 Majority participation in AlcaSynn 2006-2007 Development focus on tolperisone, licensing and marketing in Germany, launch in Germany 2008 Rounding off of the radiological portfolio through the inclusionof an MRT imaging agent Development of a new high-purity form of tolperisone as a new chemical entity (NCE) US patent for PVP hypericine (formulation and use of the active ingredient) First patent granted for improved galantamine production process 2009 European registration dossiers filed for tolperisone and MRT imaging agent 2010 Marketing authorisation (DCP) for MRT imaging agent in Europe and US approval for Scanlux (x-ray imaging agent) Out-licensing of Agileo (tolperisone formulation) for Turkey Development focus on PVP hypericin: clinical trials of PVP hypericin in the diagnosis and therapy of bladder cancer Stock exchange: Listing in the MID-MARKET of the Vienna Stock Exchange since February 2010 / Frankfurt: Change to the General Standard of the Frankfurt Stock Exchange completed with effect from May 2010 Exclusive distribution agreement for radiological products in Spain, Portugal and Latin America with IBEROINVESA Pharma SL 2011 The acquisition of Alvetra & Werfft GmbH: Veterinary medical product portfolio and synergy effects in administration, sales and drug development Radiology: new distribution partnerships in Iran, Russia and Indonesia Capital increase in Q1 funds future development of Sanochemia and increases free float to 40% Final report on Vidon (bladder cancer diagnostic) confirms results of successful Phase IIa clinical trial |
| Сайт: | http://www.sanochemia.at |
